MX2012009576A - Formas de rifaximina y usos de la misma. - Google Patents

Formas de rifaximina y usos de la misma.

Info

Publication number
MX2012009576A
MX2012009576A MX2012009576A MX2012009576A MX2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A MX 2012009576 A MX2012009576 A MX 2012009576A
Authority
MX
Mexico
Prior art keywords
rifaximin
forms
relates
present
therapeutic methods
Prior art date
Application number
MX2012009576A
Other languages
English (en)
Other versions
MX353827B (es
Inventor
Karen S Gushurst
Donglai Yang
Petinka Vlahova
Jeffrey S Stults
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2012009576A publication Critical patent/MX2012009576A/es
Publication of MX353827B publication Critical patent/MX353827B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a formas polimórficas de rifaximina, a su uso en preparaciones medicinales y a métodos terapéuticos que las utilizan.
MX2012009576A 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma. MX353827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (en) 2010-02-19 2011-02-16 Forms of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
MX2012009576A true MX2012009576A (es) 2012-12-05
MX353827B MX353827B (es) 2018-01-31

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009576A MX353827B (es) 2010-02-19 2011-02-16 Formas de rifaximina y usos de la misma.

Country Status (21)

Country Link
US (5) US8486956B2 (es)
EP (1) EP2536734B1 (es)
JP (2) JP2013520427A (es)
KR (1) KR20120140244A (es)
CN (2) CN102834398A (es)
AU (3) AU2011218258B2 (es)
BR (1) BR112012020863A2 (es)
CA (1) CA2790332A1 (es)
CR (1) CR20120449A (es)
EA (1) EA201270722A1 (es)
GE (2) GEP20156230B (es)
HK (1) HK1179608A1 (es)
IL (1) IL221299A (es)
MA (1) MA34058B1 (es)
MX (1) MX353827B (es)
MY (1) MY158992A (es)
NZ (1) NZ601670A (es)
SG (1) SG183188A1 (es)
TN (1) TN2012000414A1 (es)
WO (1) WO2011103120A1 (es)
ZA (1) ZA201206227B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
MX2010009389A (es) 2008-02-25 2010-11-22 Salix Pharmaceuticals Ltd Formas de rifaximina y sus usos.
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
SG10201507035UA (en) * 2010-06-03 2015-10-29 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
EA033370B1 (ru) 2010-07-12 2019-10-31 Salix Pharmaceuticals Ltd Составы рифаксимина и их применение
CN103221032A (zh) * 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
ES2682965T3 (es) 2011-02-11 2018-09-24 Salix Pharmaceuticals, Ltd. Formas de rifaximina y sus usos
EP2705042A1 (en) * 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EA032705B1 (ru) 2013-04-12 2019-07-31 Альфасигма С.П.А. Способ лечения или предупреждения энтеропатии
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2742106T3 (es) 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
WO2006012470A1 (en) * 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
DK1698630T3 (da) * 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
KR101480732B1 (ko) * 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
MX2010009389A (es) 2008-02-25 2010-11-22 Salix Pharmaceuticals Ltd Formas de rifaximina y sus usos.
WO2009137672A1 (en) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
CA2737528A1 (en) 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
US20120214833A1 (en) 2009-10-27 2012-08-23 Lupin Limited Solid dispersion of rifaximin
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
SG10201507035UA (en) * 2010-06-03 2015-10-29 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ES2682965T3 (es) * 2011-02-11 2018-09-24 Salix Pharmaceuticals, Ltd. Formas de rifaximina y sus usos

Also Published As

Publication number Publication date
US8569326B2 (en) 2013-10-29
AU2011218258B2 (en) 2015-11-05
AU2014246594B2 (en) 2016-09-15
HK1179608A1 (zh) 2013-10-04
IL221299A (en) 2017-11-30
TN2012000414A1 (en) 2014-01-30
US20140179916A1 (en) 2014-06-26
MA34058B1 (fr) 2013-03-05
US9034892B2 (en) 2015-05-19
US20100174064A1 (en) 2010-07-08
EP2536734A1 (en) 2012-12-26
AU2014246594A1 (en) 2014-10-30
US20160200738A1 (en) 2016-07-14
JP2016094416A (ja) 2016-05-26
WO2011103120A1 (en) 2011-08-25
SG183188A1 (en) 2012-09-27
AU2011218258A1 (en) 2012-08-30
NZ601670A (en) 2014-11-28
US20120316334A1 (en) 2012-12-13
MY158992A (en) 2016-11-30
US20140141081A1 (en) 2014-05-22
BR112012020863A2 (pt) 2016-06-21
MX353827B (es) 2018-01-31
CA2790332A1 (en) 2011-08-25
US8486956B2 (en) 2013-07-16
IL221299A0 (en) 2012-10-31
EP2536734A4 (en) 2013-06-26
EA201270722A1 (ru) 2013-03-29
JP2013520427A (ja) 2013-06-06
AU2016269529A1 (en) 2017-01-05
KR20120140244A (ko) 2012-12-28
ZA201206227B (en) 2018-12-19
AU2016269529B2 (en) 2018-06-07
CR20120449A (es) 2012-11-29
GEP20156230B (en) 2015-01-26
CN102834398A (zh) 2012-12-19
CN105254647A (zh) 2016-01-20
GEP201706745B (en) 2017-10-10
EP2536734B1 (en) 2016-08-31
US9546183B2 (en) 2017-01-17
US9273066B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
TN2012000414A1 (en) Forms of rifaximin and uses thereof
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
HK1252481A1 (zh) 疏水性治療劑的製劑、其製備方法及應用
MY158257A (en) Forms of rifaximin and uses thereof
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12018501404A1 (en) Forms of rifaximin and uses thereof
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
IN2012DN01920A (es)
NZ629697A (en) Human anti-cd27 antibodies, methods and uses
WO2012030993A3 (en) Skin compositions and methods of use thereof
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
MX349004B (es) Nuevos compuestos.
GB201106750D0 (en) Novel compounds
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX366899B (es) Nuevos compuestos.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
UA110103C2 (uk) Модифікований туберкульозний антиген
PH12014501991B1 (en) Phenicol antibacterials
IN2014DN06104A (es)
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
MX2013008559A (es) Derivados de leptina.
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain

Legal Events

Date Code Title Description
FG Grant or registration